Treatment of DVT in a Person with Factor V Leiden Deficiency

Initial Treatment Approach

For a patient with DVT and Factor V Leiden mutation who has never had a previous clot, the American College of Chest Physicians recommends a direct oral anticoagulant (DOAC) such as apixaban, dabigatran, edoxaban, or rivaroxaban for a minimum of 3 months of treatment 1, 2
For acute DVT treatment, the American College of Chest Physicians recommends beginning with a DOAC rather than vitamin K antagonist (VKA) therapy due to superior efficacy and safety profile 1
Early ambulation is suggested over bed rest for patients with DVT, according to the American College of Chest Physicians 1
Home treatment is recommended for patients with DVT whose home circumstances are adequate, as suggested by the American College of Chest Physicians 1

All patients with acute DVT should receive anticoagulant therapy for a minimum of 3 months, according to the American College of Chest Physicians 1, 2
For DVT provoked by a major transient risk factor, 3 months of anticoagulation is recommended without extended therapy, as suggested by the American College of Chest Physicians 1, 2

There is no evidence that knowledge of Factor V Leiden mutation status affects anticoagulation treatment decisions to avoid recurrence, according to Genetics in Medicine 3, 4, 5
The risk-benefit balance for asymptomatic family members who are heterozygous for Factor V Leiden is unfavorable for anticoagulation due to low absolute risk for VTE, as reported in Genetics in Medicine 5, 7

For treatment of acute DVT, apixaban, dabigatran, edoxaban, or rivaroxaban are recommended over VKA therapy, according to the American College of Chest Physicians 1
If using warfarin, the American College of Chest Physicians recommends maintaining a therapeutic INR range of 2.0-3.0 (target INR 2.5) 1

The decision for extended anticoagulation should be based on whether the DVT was provoked or unprovoked, the patient's bleeding risk, and the presence of persistent risk factors, as suggested by the American College of Chest Physicians 1, 2
For patients with unprovoked DVT or DVT with persistent risk factors, extended anticoagulation with a DOAC is recommended, according to the American College of Chest Physicians 1

Regular reassessment of the benefit-risk ratio is necessary for patients on extended anticoagulation therapy, as recommended by the American College of Chest Physicians 2
Patients should be educated about potential drug interactions that may affect bleeding risk, according to Praxis Medical Insights 6